UVA Health has joined the ACTIV-6 study in the US to analyse two repurposed therapeutics to potentially treat mild-to-moderate Covid-19.
As part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) funded by the US National Institutes of Health, the double-blind, randomised trial will analyse the efficacy of the repurposed therapies, fluvoxamine and ivermectin.
A selective serotonin reuptake inhibitor (SSRI), fluvoxamine is prescribed to treat depression. Ivermectin is indicated for the treatment of parasitic infections.
Based on sepsis research carried out at the UVA Department of Neuroscience, fluvoxamine was chosen as a potential Covid-19 therapy.
Led by the National Center for Advancing Translational Sciences, the trial will enrol approximately 15,000 subjects.
Participants will be aged 30 years and above, tested positive for Covid-19 within the past ten days and have a minimum of two symptoms for seven days or less.
Fatigue, headache, breathing problems, cough, nausea, fever, body aches, vomiting, diarrhoea, chills, sore throat, nasal symptoms and/or loss of sense of smell or taste will be included as the symptoms.
The participants can take part in the study in the at-home setting and medications will be shipped to them at no cost. Their symptoms will be monitored for more than 90 days using online surveys.
UVA Health trial principal investigator Patrick Jackson said: “While we have some great new drugs for Covid-19 in outpatients, like Paxlovid and sotrovimab, supplies are limited and it’s still important to find potential new treatments.
“Because the drugs we’re studying are cheap and widely available, they could have a huge global impact if we find they’re effective for Covid-19 treatment.”